-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Tromantadine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/53783-83-8.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 53783-83-8 |
| Description | Tromantadine is a topical antiherpetic drug that has two independent actions on herpes simplex virus type 1 (HSV-1) replication: early, during virus binding or penetration and late, after the initiation of DNA synthesis. |
Product Information
| Synonyms | N-(1-adamantyl)-2-[2-(dimethylamino)ethoxy]acetamide; D 41; N-(1-adamantyl)-2-(2-dimethylaminoethoxy)acetamide; tromantadin; tromantadine; tromantadine monohydrochloride; tromantadine monohydrochloride, monohydrate; tromantidine; Viru-Merz; Viru-Merz serol; Viru-Serol |
| Molecular Weight | 280.41 |
| Molecular Formula | C16H28N2O2 |
| Canonical SMILES | CN(C)CCOCC(=O)NC12CC3CC(C1)CC(C3)C2 |
| InChI | InChI=1S/C16H28N2O2/c1-18(2)3-4-20-11-15(19)17-16-8-12-5-13(9-16)7-14(6-12)10-16/h12-14H,3-11H2,1-2H3,(H,17,19) |
| InChIKey | UXQDWARBDDDTKG-UHFFFAOYSA-N |
| Boiling Point | 434.5±28.0 °C at 760 Torr |
| Flash Point | 216.6°C |
| Purity | ≥99.0% |
| Density | 1.09±0.1 g/cm3 |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Colorless to light yellow (Oil) |
| Storage | Store in a cool and dry place (or refer to the Certificate of Analysis). |
| Complexity | 326 |
| Exact Mass | 280.215078140 |
| Index Of Refraction | 1.533 |
| In Vitro | Tromantadine inhibits herpes simplex virus type 1 (KOS strain)-induced cytopathic effect and virus replication with limited toxicity to the cells. Vero and HEp-2 cells tolerate up to 2 mg of Tromantadine per 2x106 cells for 24-, 48-, or 96-h incubation periods with little change in cell morphology. Treatment of the cells with 10 to 50 μg of Tromantadine reduces herpes simplex virus-induced cytopathic effect. Treatment with 100 to 500 μg of Tromantadine inhibits herpes simplex virus-induced cytopathic effect and reduces virus production. Complete inhibition of virus production is observed with treatments of 500 μg to 1 mg. The antiherpetic activity of Tromantadine is dependent upon the viral inoculum size and the time of addition of the compound with respect to infection. Virion synthesis and viral polypeptide synthesis are inhibited by addition of Tromantadine at the time of infection or 4 h postinfection. Tromantadine raises the bilayer to hexagonal phase transition temperature of synthetic phosphatidylethanolamines and is less disruptive to phospholipid packing. Tromantadine acts similar to cyclosporin A, previously demonstrated to inhibit viral-induced cell-cell fusion. |
| PSA | 41.57000 |
| Target | HSV |
| XLogP3-AA | 2.1 |
